Exenatide

What it means

Exenatide is a lab-made version of exendin-4, a hormone first found in the saliva of the Gila monster lizard. It acts on the same receptor as human GLP-1 but resists breakdown longer, which made it the starting point for the whole drug class.

The FDA approved Byetta in 2005 for blood sugar control in type 2 diabetes. A once-weekly version, Bydureon, followed later. The maker discontinued both brands in the US in 2024 for business reasons, not safety concerns, and an FDA-approved generic exenatide pen that references Byetta became available after that.

Exenatide has a short half-life of a few hours, which is why the original version was injected twice a day before meals. Weight loss in diabetes trials was modest compared with newer weekly medicines, and exenatide has never been approved for weight management.

Side effects follow the class pattern: nausea, vomiting and diarrhea, mostly early on, and a higher risk of low blood sugar when combined with a sulfonylurea.

Why it matters

Exenatide explains where today's GLP-1 medicines came from and why longer half-lives changed dosing from twice a day to once a week.